Ireland's Life Sciences sector has grown rapidly from modest beginnings in the 1960s to reach global significance. Collaborative clusters in Pharmaceutical, Biotechnology, Medical Devices and Diagnostics have been a key element behind this remarkable growth in a sector that accounts for 39% of national exports (c. €62 bn, CSO 2020). Ireland is now the third largest exporter of pharmaceuticals globally (UN International Trade Statistics Database).
The sector continues to develop and evolve, more recently Ireland has expanded its global hub beyond commercialisation to include innovation, digitalisation and next generation technologies.
Circa €2 billion invested in Biopharma R&D by IDA client companies annually with an additional €1Billion in Cap Ex added each year.
Companies, research and government link to create the Irish advanced manufacturing landscape.
9 of the world's top
85+ pharmaceutical companies
30,000 people employed
Unrivalled compliance record
50 FDA approved
Ireland has one of the youngest and most highly educated populations in Europe. This provides a rich and strong pool of talent for the sector, which continues to benefit from high levels of investment in third-level education and the growth of collaborative clusters.
Ireland’s universities in the fields of Engineering, Chemistry, Biochemistry and Bio Technology have strong cooperative links with the sector. Feedback from the industry in terms of its skills needs feeds directly into the universities and drives Ireland’s pursuit of Biopharmaceutical academic excellence.
Manufacturing excellence in Biopharmaceuticals is a hallmark of Ireland's success in the sector. This is constantly driving growth and Ireland has seen continued capital investment averaging at €1 billion per annum over the last 10 years. Circa €2 billion invested annually in Biopharma R&D by IDA client companies.
A key driver of operational and research excellence is practitioner-to-practitioner knowledge sharing. With strong clusters based in Dublin and Cork, and rapidly developing hotspots around Sligo, Waterford and Dundalk, organisations, such as the Irish Centre for Business Excellence and IBEC, work with the IDA to facilitate best practice-sharing between companies.
The government funded The National Institute for Bioprocessing Research and Training (NIBRT), a world-class institute that provides training and research solutions for the bioprocessing industry. NIBRT provides sector specific training to over 4,000 people annually and operates from its state-of-the-art, multi-functional building specifically built to serve the needs of Ireland’s biopharma sector.
Ireland has an exemplary compliance record with the regulatory agencies, including the FDA and EMA, who collaborate and work closely with Ireland’s Health Products Regulatory Authority (HPRA) to achieve trouble-free compliance.
Ireland’s regulatory track record is excellent. The Health Product Regulatory Authority (HPRA), operates in accordance with European and global standard procedures boasts an excellent international reputation in regulatory compliance.
The HPRA are committed to supporting all stakeholders in managing the regulatory and operational implications arising from Brexit. The HPRA has established an internal working group to ensure that Ireland is prepared for the UK’s withdrawal from the EU.
Ireland has a significant track record of clinical and academic research excellence. The Irish government in its National Development Plan - Project Ireland 2040 has committed to funding research to further bolster Ireland’s reputation as a growing hub for research and development. The National Development Plan is a ten year strategy in support of infrastructure priorities to the higher education sector.
Key to Ireland’s attractiveness to FDI is the quality of our education system and of our graduates. Ireland has the highest level of STEM graduates per capita in the EU. A new dedicated Government Department for Higher Education, Innovation and Science established in July 2020.
The National Institute for Bioprocess Research and Training (NIBRT), created from a €60million investment by the IDA, gave practical training to over 4,000 people in 2019. Senior executives from the sector sit on the NIBRT board in the knowledge that the availability of suitably trained staff is a key determinant of success in Biopharmaceutical manufacturing. NIBRT have identified ATMPs as a future growth area and are in the process of implementing a cap investment plan to deliver on this project.
IDA Ireland provide direct funding to companies to carry out in house RD&I and Training.(RD&I) grant is open to application by clients of IDA Ireland wishing to develop innovative products, processes and services it aims to increase the number of companies performing effective RD&I in Ireland.
In Addition to in house R&D there are multiple opportunities for research collaborations. Majority of these are funded through Science Foundation Ireland. (SFI) with an annual budget of circa €200 million funds a significant portion of basic research in the Biopharmaceutical sector, especially with regards to understanding cancer, autoimmune disease and Alzheimer’s.
Explore the current business landscape in Ireland and see what's happening on the ground now.
Takeda Ireland, a subsidiary of Takeda Pharmaceutical Company Ltd, today celebrates the opening of a cell therapy production facility at its Grange Castle site. The commercial scale cell therapy production facility is the first of its kind in Ireland and will play an important role in supplying European, US and Canadian markets with a cell therapy treatment option for patients.
EirGen Pharma announce the expansion of its Oral Solid Dose business in Waterford.
Investment has the potential to create 180 new full-time jobs.
Expansion will add to the existing global manufacturing capacity, allowing the company to reach patients with crucial biomedicines faster.
Amgen announced an investment of $100 million today for the construction of a new vial filing line with ‘state of the art’ technology and new site infrastructure at its manufacturing plant in Dun Laoghaire, Co Dublin.
Tánaiste & Minister for Enterprise, Trade and Employment Leo Varadkar TD and IDA Ireland today welcomed the announcement by global pharmaceutical and biotechnology company AstraZeneca that it is to invest $360M in a new manufacturing facility in Ireland, creating 100 jobs.
Bio-Techne Corporation (NASDAQ:TECH) today announced the opening of its new Ireland facility located in Dublin. This new facility reflects Bio-Techne’s commitment to supporting the broader life sciences industry in Europe as well as expectations for continued growth and staffing needs in this geography.
Takeda Ireland, a subsidiary of Takeda Pharmaceutical Company Ltd, today announced a €36 million investment in its Grange Castle facility. The investment will support the expansion of the company’s cell therapy production facility and create approximately 100 new jobs over the next three years.
IQVIA, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced the creation of 170 remote jobs throughout Ireland.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced plans to invest approximately €7 million in the company’s Irish operations, opening a new base in Dublin and creating 140 jobs.
Ireland is the leading destination for pharmaceutical activity, 85+ biopharmaceutical companies call Ireland home, Ireland is the third largest exporter of pharmaceuticals globally and 50 FDA-approved manufacturing plants are located here.
Allergan plc, the global integrated biopharmaceutical leader headquartered in Ireland, today marked the opening of its €160m state-of-the-art Biologics 2 facility at its Westport Campus in Co. Mayo, Ireland. The new facility will create 63 jobs and enhance Ireland’s position as a strategic global hub for Allergans’ flagship products, including their botulinum toxin brand. This brings Allergan’s total investment in Ireland since it began operations in the country to more than €750m.
Minister for Business, Enterprise & Innovation Heather Humphreys TD today confirmed that WuXi Vaccines, a subsidiary of WuXi Biologics (stock code: 2269.HK), is planning to build a $240 million vaccine production facility on the newly established WuXi Biologics Campus in Dundalk, bringing 200 additional new jobs to the town over five years. The new investment, for which a planning application was submitted to Louth County Council last month is being supported by the Irish Government through IDA Ireland will bring total employment on WuXi Biologics’ Dundalk Campus to 600 by 2024.
Ringaskiddy, Co. Cork, Ireland, October 7, 2019 - Janssen Sciences Ireland UC, part of the Johnson & Johnson family of companies, today officially opened its new manufacturing building in Ringaskiddy, Co. Cork. The company has operated a biopharmaceutical supply chain facility on its 40-hectare site in Ringaskiddy since 2005.
Everything you need to know about investing in Ireland in 2019 including information on economy, talent, tax, commercial property and more.
Every company that wants to grow will reach a point where it needs to expand into new markets. Doing it right means setting up operations closer to those customers.
It’s a big step, but it’s one that many others have taken before. For this blog, we spoke to senior leaders at leading tech companies that expanded into Ireland. They shared their advice on getting a fast and frictionless start, with five practical tips for others planning to grow their business internationally.
Facilitates production of an oncology treatment for global markets puts Drug Substance, Drug Product, Packaging, Innovation and Quality Control all under one roof.
Today, Minister for Business, Enterprise and Innovation, Heather Humphreys T.D., visited Pfizer Ringaskiddy almost 50 years to the day the company first came to Ireland. During her visit, the Minister recognised the significance of this anniversary and the substantial investment of Pfizer in Ireland over the last five decades. The Minister toured part of the large-scale manufacturing site, visiting the New Product Technology Lab, a state of the art $30 Million facility. The visit is part of a series of events to celebrate the company’s 50th anniversary in Ireland.
Global life-science innovation leader, Allergan, which is headquartered in Ireland and operates four facilities here, has announced a €65 million capital investment programme for 2019 to facilitate the continued expansion of the company’s state-of-the art laboratories and manufacturing campuses at Westport in County Mayo and Clonshaugh in north Dublin. The Westport facility has created 63 new highly skilled jobs, bringing total employment in Ireland to more than 2,000 across the country. One in ten employees in Allergan’s global workforce is based in Ireland.
Greenfield Global Inc., Canada’s largest producer of alcohol and fuel ethanol, and one of the largest alcohols and solvents companies in North America, today announced plans to establish a new EU manufacturing headquarters in Portlaoise, Ireland.
Creation of 100 new jobs by global human data sciences innovator
Zimmer Biomet, is celebrating a decade in Ireland. A leading employer in Shannon and Oranmore, Galway, the company’s footprint in Ireland now features two state-of-the-art manufacturing facilities plus a professional education centre that attracts healthcare professionals from around the world.
Move to new, larger premises in Waterford signals company’s plans to develop a flagship facility to spearhead its activities in Ireland and worldwide
Explore the current business landscape in Ireland and see what's happening on the ground now.
You'll find us responsive to your needs, proactive, professional and willing to go the extra mile.
We have 28 Offices worldwide helping support companies expand their operations in Ireland.
To consent to the use of ALL cookies click “I Accept”. You may visit Cookies Preference to manage which cookies we may use.